BANGALORE, India and SARATOGA, Calif. and ADELAIDE, Australia, Dec. 7, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is presenting the research findings on its novel, best-in-class, dual-acting adenosine antagonists BWC2094 and BWC2562 with the potential to treat a variety of hard-to-treat cancers, at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 in Geneva, Switzerland on 7th December.
Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark
BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 22, 2023 /PRNewswire/ -- Bugworks Research, a clinical-stage biopharmaceutical company, has engaged Dr. Renu Swarup as a honorary member of the Global Advisory Board. Dr. Swarup is the former Secretary, Department of Biotechnology, Government of India and brings in more than three decades of experience in the biotech sector.
Indian startup Bugworks Research, a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals have announced the launch of a first-of-its-kind collaboration. Bugworks develops best-in-class, novel therapies for cancer and infectious diseases & has set up a dedicated research center within Cytecare, which is committed to excellence in treating cancer patients.
BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration. Bugworks develops best-in-class, novel therapies for cancer and infectious diseases & has set up a dedicated research center within Cytecare, which is committed to excellence in treating cancer patients.
Indian biotech chiefs from Biocon and Bugworks Research India emphasized the need for a policy similar to the Bayh-Dole Act in the US. This is because they see that it would be the only way to accelerate and allow universities, non-profit research centres and small businesses to hold a patent and commercialize inventions developed under government funded research programmes. Further, it will drive technology transfers, protect intellectual property and enable faster lab-to-market process.
Bugworks Research announced that the first human dose was administered in a phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), supported by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).